Oncaspar 3,750 unit/5 ML vial 5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEH7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $40,718
Award facts
- Contract value 100% obligated
- $40,717.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 3,750 units of Oncaspar 5 ml vials valued at $40,717.98. The award, issued on January 29, 2026, with an ultimate completion date of February 20, 2026, carries a firm fixed-price structure with no small business set-aside designation, indicating the contractor competed in open federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with demonstrated performance across multiple therapeutic categories and product lines since its system registration in 2001. The company's portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals including oncology treatments, immunosuppressants, and emergency medications. The PPV-G GEN V contract, awarded November 13, 2025, with a $499,999,999 ceiling and completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor to serve recurring medical supply needs of military healthcare facilities worldwide through a 30-month base period with three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FMEH7?
SPE2DR26FMEH7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FMEH7 worth?
The government has obligated $40,718 on SPE2DR26FMEH7.
Is contract SPE2DR26FMEH7 an order under another contract?
Yes. SPE2DR26FMEH7 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEH7 competed?
The extent of competition for SPE2DR26FMEH7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award